Paving the Path to Prevention: Managing Early Treatments for T1D Progression - Episode 6

Overview of Teplizumab for Delaying Onset and Progression of Type 1 Diabetes

January 20, 2025

Javier Morales, MD, FACP, FACE , Shira Eytan, MD, FACE, Bethany Kinsey, NP, Quentin Van Meter, MD, David Robertson, MD

Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.

EP. 1: Living with Type 1 Diabetes

EP. 2: Screening Guidelines for Type 1 Diabetes

EP. 3: Stages and Symptoms of Type 1 Diabetes

EP. 4: Impact of Delayed Intervention in Stage 2 Type 1 Diabetes

EP. 5: Types of Antibody Screening Tests for Type 1 Diabetes

Now Viewing

EP. 6: Overview of Teplizumab for Delaying Onset and Progression of Type 1 Diabetes

EP. 7: Patient Selection For Teplizumab and Infusion Process

EP. 8: Final Thoughts on Identifying and Managing Patients with T1D